Education

Bachelor of Science (Hons) with specialization in biomedical sciences,  Department of Microbiology, National University of Singapore, 2012

Current Position

Ph.D student in National University of Singapore, Yong Loo Lin School of Medicine

Senior Research Assistant in Duke-NUS Graduate Medical School (Program in Emerging Infectious Disease)

Publications

1. Tay, M. Y., Smith, K., Ng, I. H., Chan, K. W., Zhao, Y., Ooi, E. E., Lescar, J., Luo, D., Jans, D. A., Forwood, J. K. and Vasudevan, S. G. (2016). The C-terminal 18 Amino Acid Region of Dengue Virus NS5 Regulates its Subcellular Localization and Contains a Conserved Arginine Residue Essential for Infectious Virus Production. PLoS Pathog 12(9): e1005886.
2. Sung, C., Wei, Y., Watanabe, S., Lee, H. S., Khoo, Y. M., Fan, L., Rathore, A. P., Chan, K. W., Choy, M. M., Kamaraj, U. S., Sessions, O. M., Aw, P., de Sessions, P. F., Lee, B., Connolly, J. E., Hibberd, M. L., Vijaykrishna, D., Wijaya, L., Ooi, E. E., Low, J. G. and Vasudevan, S. G. (2016). Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. PLoS Negl Trop Dis 10(8): e0004851.
3. Croci, R., Bottaro, E., Chan, K. W., Watanabe, S., Pezzullo, M., Mastrangelo, E. and Nastruzzi, C. (2016). Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin. Int J Biomater 2016:8043983.
4. Fraser, J. E., Wang, C., Chan, K. W., Vasudevan, S. G. and Jans, D. A. (2016). Novel dengue virus inhibitor 4-HPR activates ATF4 independent of protein kinase R-like Endoplasmic Reticulum Kinase and elevates levels of eIF2alpha phosphorylation in virus infected cells. Antiviral Res 130: 1-6.
5. Watanabe, S., Chan, K. W., Dow, G., Ooi, E. E., Low, J. G. and Vasudevan, S. G. (2016). Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy. Antiviral Res 127: 10-19.
6. Chan, K. W., Watanabe, S., Kavishna, R., Alonso, S. and Vasudevan, S. G. (2015). Animal models for studying dengue pathogenesis and therapy. Antiviral Res 123: 5-14.
7. Zhao, Y., Soh, T. S., Chan, K. W., Fung, S. S., Swaminathan, K., Lim, S. P., Shi, P. Y., Huber, T., Lescar, J., Luo, D. and Vasudevan, S. G. (2015). Flexibility of NS5 Methyltransferase-Polymerase Linker Region Is Essential for Dengue Virus Replication. J Virol 89(20): 10717-10721.
8. Watanabe, S., Chan, K. W., Wang, J., Rivino, L., Lok, S. M. and Vasudevan, S. G. (2015). Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. J Virol 89(11): 5847-5861.
9. Zhao, Y., Soh, T. S., Zheng, J., Chan, K. W., Phoo, W. W., Lee, C. C., Tay, M. Y., Swaminathan, K., Cornvik, T. C., Lim, S. P., Shi, P. Y., Lescar, J., Vasudevan, S. G. and Luo, D. (2015). A crystal structure of the Dengue virus NS5 protein reveals a novel inter-domain interface essential for protein flexibility and virus replication. PLoS Pathog 11(3): e1004682.
10. Tay, M. Y., Saw, W. G., Zhao, Y., Chan, K. W., Singh, D., Chong, Y., Forwood, J. K., Ooi, E. E., Gruber, G., Lescar, J., Luo, D. and Vasudevan, S. G. (2015). The C-terminal 50 amino acid residues of dengue NS3 protein are important for NS3-NS5 interaction and viral replication. J Biol Chem 290(4): 2379-2394.
11. Li, L., Basavannacharya, C., Chan, K. W., Shang, L., Vasudevan, S. G. and Yin, Z. (2015). Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease. Chem Biol Drug Des 86(3): 255-264.
12. Low, J. G., Sung, C., Wijaya, L., Wei, Y., Rathore, A. P., Watanabe, S., Tan, B. H., Toh, L., Chua, L. T., Hou, Y., Chow, A., Howe, S., Chan, W. K., Tan, K. H., Chung, J. S., Cherng, B. P., Lye, D. C., Tambayah, P. A., Ng, L. C., Connolly, J., Hibberd, M. L., Leo, Y. S., Cheung, Y. B., Ooi, E. E. and Vasudevan, S. G. (2014). Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 14(8): 706-715.
13. Fraser, J. E., Watanabe, S., Wang, C., Chan, W. K., Maher, B., Lopez-Denman, A., Hick, C., Wagstaff, K. M., Mackenzie, J. M., Sexton, P. M., Vasudevan, S. G. and Jans, D. A. (2014). A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. J Infect Dis 210(11): 1780-1791.
14. Loh, C. C., Suwanarusk, R., Lee, Y. Q., Chan, K. W., Choy, K. Y., Renia, L., Russell, B., Lear, M. J., Nosten, F. H., Tan, K. S. and Chow, L. M. (2014). Characterization of the commercially-available fluorescent chloroquine-BODIPY conjugate, LynxTag-CQGREEN, as a marker for chloroquine resistance and uptake in a 96-well plate assay. PLoS One 9(10): e110800.
15. Tan, K. H., Ki, K. C., Watanabe, S., Vasudevan, S. G. and Krishnan, M. (2014). Cell-based flavivirus infection (CFI) assay for the evaluation of dengue antiviral candidates using high-content imaging. Methods Mol Biol 1138: 99-109.
16. Tay, M. Y., Fraser, J. E., Chan, W. K., Moreland, N. J., Rathore, A. P., Wang, C., Vasudevan, S. G. and Jans, D. A. (2013). Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res 99(3): 301-306.